Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause
Completed
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 3
2004-09-01
The purpose of this study is to assess the safety and efficacy of desvenlafaxine succinate
(DVS) for treatment of moderate to severe vasomotor symptoms (VMS) that are associated with
menopause, and also to assess the effects of DVS on sleep parameters and health outcomes
indicators.
Study Evaluating Desvenlafaxine Succinate Sustained-release (DVS SR) in Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy
Terminated
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 3
2006-03-01
The purpose of this study is to evaluate the safety and efficacy of DVS SR in the treatment
of neuropathic pain associated with diabetic peripheral neuropathy.
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women
Completed
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 3
2006-09-01
Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine
reuptake inhibitor (SNRI). The sustained-release (SR) formulation, DVS SR, is being studied
in the development program for the treatment of major depressive disorder (MDD), for
vasomotor symptoms (VMS) associated with menopause, and for pain associated with peripheral
diabetic neuropathy, as well as for the treatment of fibromyalgia syndrome. This study will
investigate the safety, efficacy, and tolerability of DVS SR in women with MDD who are peri-
and postmenopausal.
Study of the Safety and Efficacy of Desvenlafaxine Succinate for Vasomotor Symptoms in Postmenopausal Women
Completed
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 3
2006-06-01
The purpose of this study is to evaluate the efficacy and safety of 100 mg and 150 mg of DVS
SR, an extended release form of desvenlafaxine succinate, in comparison to placebo for the
treatment of Vasomotor Symptoms (VMS) associated with menopause in a population of
postmenopausal women.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
